Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: A randomized controlled trial

Haematologica

Volumn 100, Issue 6, 2015, Pages 842-848

  Mielcarek, Marco ^a   Furlong, Terrence ^a   Storer, Barry E ^a   Green, Margaret L ^a   McDonald, George B ^a   Carpenter, Paul A ^a   Flowers, Mary E D ^a   Storb, Rainer ^a   Boeckh, Michael ^a   Martin, Paul J ^a  

^a USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CALCINEURIN INHIBITOR; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISONE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER DYSFUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RISK; TOXICITY; TREATMENT WITHDRAWAL; ACUTE DISEASE; CHEMICALLY INDUCED; CLINICAL TRIAL; GRAFT VS HOST DISEASE; INFANT; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; EXANTHEMA; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; INFANT; MALE; MIDDLE AGED; PREDNISONE; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930531908     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.118471     Document Type: Article

References (17)

1. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295-304.
2. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graftversus- host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome. Blood. 1990;75(4):1024-1030.
3. Shlomchik WD. Graft-versus-host disease (Review). Nat Rev Immunol. 2007;7(5):340-352.
4. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314(12):729-735.
5. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graftversus- host disease: initial treatment. Blood. 1990;76(8):1464-1472.
6. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graftversus- host disease: secondary treatment. Blood. 1991;77(8):1821-1828.
7. Antin JH, Chen AR, Couriel DR, Ho VT, Nash RA, Weisdorf D. Novel approaches to the therapy of steroid-resistant acute graftversus- host disease. Biol Blood Marrow Transplant. 2004;10(10):655-668.
8. van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: A multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood. 1998; 92(7):2288-2293.
9. Mielcarek M, Storer BE, Boeckh M, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood. 2009;113(13):2888-2894.
10. McDonald GB, Bouvier M, Hockenbery DM, et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus- host disease: A randomized, controlled trial. Gastroenterology. 1998;115(1):28-35.
11. Hockenbery DM, Cruickshank S, Rodell TC, et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood. 2007;109(10):4557-4563.
12. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
13. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)- specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919.
14. Ramesh R, Kozhaya L, McKevitt K, et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med. 2014;211(1):89-104.
15. Rezvani AR, Storer BE, Storb RF, et al. Decreased serum albumin as a biomarker for severe acute graft-vs-host disease after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(11):1594-1601.
16. Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013;369(6):529-539.
17. Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versushost disease. Blood. 2009;113(2):273-278.